Rznomics Announces FDA RMAT Designation for RZ-001 in Hepatocellular Carcinoma
SEOUL, South Korea, May 8, 2026 Rznomics announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative...
Alzheimer’s Disease Autoimmune Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology Bispecific Antibody cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy Immuno-Oncology immunology Immunotherapy Medical Device Medical Devices MedTech medtech innovation Monoclonal Antibody Neurodegenerative Disease Oncology oncology innovation Ophthalmology Orphan Drug orphan drug designation Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory approval regulatory compliance targeted therapy
SEOUL, South Korea, May 8, 2026 Rznomics announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative...
